文献速递炎症性肠病

瑞莎珠单抗治疗克罗恩病患者的长期有效性和安全性

Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-10-24

该研究在一个大型三级中心前瞻性监测了开始瑞莎珠单抗治疗的克罗恩病患者,134例纳入有效性分析(52%有乌司奴单抗使用史),第12、26、52周临床缓解率分别为69%、64%、54%,无激素临床缓解率分别为58%、58%、50%;乌司奴单抗经治与初治患者缓解率无统计学差异,243例安全性分析与既往文献一致。

要点

  • 第12、26、52周临床缓解率分别为69%、64%、54%,无激素临床缓解率分别为58%、58%、50%。
  • 乌司奴单抗经治患者缓解率与初治患者相比无统计学降低,多因素分析中既往乌司奴单抗治疗与1年无激素临床缓解 odds 降低无关。
  • 243例安全性分析中不良事件与既往文献一致。

核心结论

  • 长期真实世界经验显示瑞莎珠单抗在克罗恩病患者中具有有效性和安全性,乌司奴单抗初治与经治患者有效性相当。

研究设计与样本

  • 在一个大型三级中心前瞻性监测开始瑞莎珠单抗治疗的患者,有效性分析纳入有活动性腔内病变且随访至少12周者,共134例;安全性分析纳入任何适应症开始治疗的全部243例患者。

主要发现

  • 有效性分析共134例,其中70例(52%)有乌司奴单抗使用史。
  • 第12、26、52周临床缓解率分别为69%、64%、54%。
  • 第12、26、52周无激素临床缓解率分别为58%、58%、50%。
  • 乌司奴单抗经治患者缓解率与初治患者相比未达统计学显著降低;多因素分析中既往乌司奴单抗治疗与1年无激素临床缓解的 odds 降低无关。
  • 243例患者的不良事件评估与既往文献一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Risankizumab is a selective interleukin-23 inhibitor approved for the treatment of Crohn's disease (CD). We report a large long-term real-world experience with risankizumab in CD. METHODS: We performed a prospective monitoring of clinical outcomes in patients at a large tertiary center who started treatment with risankizumab. Patients with active luminal disease who had at least 12 weeks of follow-up were included in the effectiveness analysis. Harvey-Bradshaw Index, as well as C-reactive protein and fecal calprotectin, were used to monitor disease activity. Primary outcomes were clinical remission and steroid-free clinical remission rates at weeks 12, 26, and 52. Univariate analysis followed by a multivariate analysis using a logistic regression model was performed to identify predictors of steroid-free clinical remission at 1 year. All patients who started treatment with risankizumab for any indication were included in the safety analysis. RESULTS: A total of 134 patients were included in the effectiveness analysis. Seventy (52%) were ustekinumab-experienced. Clinical remission rates were 69%, 64%, and 54% at weeks 12, 26, and 52, respectively. Steroid-free clinical remission rates at 12, 26, and 52 weeks were 58%, 58%, and 50%, respectively. Remission rates in ustekinumab-experienced patients were not statistically lower compared with naïve patients, and in a multivariate analysis, prior ustekinumab treatment was not associated with lower odds of achieving steroid-free clinical remission at 1 year. Adverse effects were assessed in 243 patients and were consistent with previous literature. CONCLUSIONS: This large real-world experience with risankizumab with long-term follow-up demonstrates effectiveness and safety in patients with CD; there was comparable effectiveness in ustekinumab-naïve and ustekinumab-experienced patients.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Zinger A, Choi D, Choi N, et al. Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024. PMID: 39461462. doi:10.1016/j.cgh.2024.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。